How should I manage increased anxiety in a 19-year-old female with agoraphobia and atypical anorexia who is taking escitalopram 15 mg and had her aripiprazole (Abilify) dose increased from 2 mg to 4 mg?

Management of Increased Anxiety After Aripiprazole Dose Increase

The most likely cause of increased anxiety is the aripiprazole dose escalation from 2mg to 4mg, and you should reduce the aripiprazole back to 2mg immediately while optimizing the escitalopram dose to address the underlying anxiety disorders.

Primary Recommendation: Reduce Aripiprazole

The temporal relationship between the dose increase and symptom onset strongly suggests aripiprazole is the culprit. While aripiprazole has shown some efficacy as augmentation for anxiety in open-label studies 1, 2, anxiety and agitation are recognized adverse effects of aripiprazole, particularly early in treatment or after dose changes 3. The FDA label specifically notes that common adverse reactions include agitation and anxiety 3.

Key Action Steps:

• Immediately reduce aripiprazole back to 2mg where the patient was previously stable
• If aripiprazole augmentation is truly needed for the atypical anorexia, maintain at the lower 2mg dose
• Consider whether aripiprazole is even necessary—the evidence for atypical antipsychotics in anorexia is limited 4

Optimize SSRI Therapy for Anxiety

Escitalopram 15mg may be suboptimal for treating agoraphobia and anxiety in this patient. The guideline evidence supports that SSRIs are first-line for anxiety disorders 5, and escitalopram specifically has demonstrated efficacy in adolescent generalized anxiety disorder at doses up to 20mg 6 and in panic disorder 7, 8.

Escitalopram Optimization:

• Consider increasing escitalopram to 20mg once aripiprazole is reduced and the patient stabilizes
• Escitalopram has shown high remission rates with acceptable adverse event profiles for panic and anxiety disorders 8
• The guideline recommends dose titration at 1-2 week intervals for shorter half-life SSRIs like escitalopram 5
• Monitor closely for the first 24-48 hours after any dose change, as SSRIs can initially cause anxiety or agitation 5

Critical Monitoring Considerations

Given the combination of escitalopram and aripiprazole, obtain an ECG to assess QT interval 9. The eating disorder guideline specifically recommends ECG monitoring in patients with restrictive eating disorders who are taking medications known to prolong QTc intervals 9. Both escitalopram (particularly at higher doses) and aripiprazole can affect cardiac conduction 5, 3.

Additional Monitoring:

• Vital signs including orthostatic measurements (critical in eating disorder patients) 9
• Weight and nutritional status
• Suicidal ideation, particularly given the patient's age and SSRI use 5

Evidence Regarding Aripiprazole and Anxiety

The evidence for aripiprazole in anxiety is weak and contradictory:

• Open-label studies suggest possible benefit as SSRI augmentation 1, 2
• However, pretreatment anxious depression predicts higher rates of nervousness and agitation with both escitalopram and aripiprazole 10
• In one study, patients with anxious depression had 38% higher incidence of side effects with escitalopram and experienced significantly more nervousness and agitation 10

Treatment Algorithm Moving Forward

1. Immediate (Days 1-3): Reduce aripiprazole to 2mg
2. Week 1-2: Monitor anxiety symptoms; if improved, patient was stable at lower aripiprazole dose
3. Week 2-4: If anxiety persists despite aripiprazole reduction, increase escitalopram to 20mg (if tolerated and no QT concerns)
4. Week 6-8: Reassess response; consider adding CBT or family-based therapy per guidelines 5, 9

Pitfalls to Avoid

• Do not continue escalating aripiprazole in the face of worsening anxiety—this is likely iatrogenic
• Do not assume the anxiety is purely disease progression—medication adverse effects are common and temporally related here
• Do not overlook cardiac monitoring in a young female with an eating disorder on multiple psychotropic medications
• Ensure parental oversight of medication regimens as recommended for adolescents 5

The guideline strongly supports combination CBT and SSRI therapy for anxiety disorders in this age group 5, so ensure evidence-based psychotherapy is part of the treatment plan alongside medication optimization.